<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Certara, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/certara-inc</link>
    <description>Latest news and press releases for Certara, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 11 May 2026 10:25:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/certara-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835541578dffbe2df0e8bd8.webp</url>
      <title>Certara, Inc.</title>
      <link>https://6ix.com/company/certara-inc</link>
    </image>
    <item>
      <title>Certara Reports First Quarter 2026 Financial Results</title>
      <link>https://6ix.com/company/certara-inc/news/certara-reports-first-quarter-2026-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/certara-reports-first-quarter-2026-financial-results</guid>
      <pubDate>Mon, 11 May 2026 10:25:00 GMT</pubDate>
      <description>Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing BusinessRADNOR, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its first quarter 2026 financial results. First Quarter Highlights: Revenue was $106.9 million, compared to $106.0 million in the first quarter of 2025, representing growth of 1%. Software revenue was $49.7 million, compared to $46.4 million in the fir</description>
    </item>
    <item>
      <title>Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development</title>
      <link>https://6ix.com/company/certara-inc/news/altasciences-and-certara-announce-strategic-partnership-to-accelerate-early-drug-development</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/altasciences-and-certara-announce-strategic-partnership-to-accelerate-early-drug-development</guid>
      <pubDate>Thu, 07 May 2026 12:00:00 GMT</pubDate>
      <description>LAVAL, Québec &amp; RADNOR, Pa., May 07, 2026--Altasciences, a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs.</description>
    </item>
    <item>
      <title>Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat</title>
      <link>https://6ix.com/company/certara-inc/news/certara-enters-definitive-agreement-for-the-sale-of-its-regulatory-and-medical-writing-business-to-veristat</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/certara-enters-definitive-agreement-for-the-sale-of-its-regulatory-and-medical-writing-business-to-veristat</guid>
      <pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
      <description>Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence Updated 2026 guidance to be provided upon transaction close RADNOR, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it has entered into a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for a consideration of up to $135 million. The transaction is expected to close during</description>
    </item>
    <item>
      <title>Cerrado Gold Announces Q1 2026 Production Results at Its Minera Don Nicolas Mine in Argentina</title>
      <link>https://6ix.com/company/certara-inc/news/cerrado-gold-announces-q1-2026-production-results-at-its-minera-don-nicolas-mine-in-argentina-1</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/cerrado-gold-announces-q1-2026-production-results-at-its-minera-don-nicolas-mine-in-argentina-1</guid>
      <pubDate>Mon, 20 Apr 2026 10:00:00 GMT</pubDate>
      <description>Strong Production of 12,842 Gold Equivalent Ounces (&quot;GEO&quot;) for the 1st Quarter 2026Improved realized gold prices with close-out of hedges in January2026 Production Guidance of 50,000 to 60,000 GEO maintainedUnderground development ramping up to support increased production in Q2/Q3Exploration Program advancing rapidly to support resource growth at MDN with four drill rigs operating on siteDevelopment activities continue to progress at both the Lagoa Salgada and Mont Sorcier projects TORONTO, Apr</description>
    </item>
    <item>
      <title>Certara to Report First Quarter 2026 Financial Results on May 11th, 2026</title>
      <link>https://6ix.com/company/certara-inc/news/certara-to-report-first-quarter-2026-financial-results-on-may-11th-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/certara-to-report-first-quarter-2026-financial-results-on-may-11th-2026</guid>
      <pubDate>Thu, 09 Apr 2026 20:15:00 GMT</pubDate>
      <description>RADNOR, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the first quarter of 2026 before market open on Monday, May 11th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance.</description>
    </item>
    <item>
      <title>Cerrado Gold Announces Q4 and Annual 2025 Financial Results</title>
      <link>https://6ix.com/company/certara-inc/news/cerrado-gold-announces-q4-and-annual-2025-financial-results-17</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/cerrado-gold-announces-q4-and-annual-2025-financial-results-17</guid>
      <pubDate>Thu, 02 Apr 2026 04:26:00 GMT</pubDate>
      <description>Annual Production for 2025 of 50,238 Gold Equivalent Ounces (“GEO”); and AISC of US$1,746 per ounce, in line with guidance2026 Production guidance of 50,000 to 60,000 GEO weighted to H2/26Adjusted EBITDA of $22.3 million for Q4, and $46.1 million for the full yearCompleted hedging program provides full future leverage to high gold prices Exited the year with a strong cash position of over $22 millionManagement to host Conference Call to discuss the financial and operational results on [April 2nd</description>
    </item>
    <item>
      <title>Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib</title>
      <link>https://6ix.com/company/certara-inc/news/certara-simcypr-simulator-results-replace-ten-human-trials-for-chronic-myeloid-leukemia-cml-therapy-asciminib</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/certara-simcypr-simulator-results-replace-ten-human-trials-for-chronic-myeloid-leukemia-cml-therapy-asciminib</guid>
      <pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
      <description>Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money. RADNOR, Pa., March 03,</description>
    </item>
    <item>
      <title>Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance</title>
      <link>https://6ix.com/company/certara-inc/news/certara-reports-fourth-quarter-2025-financial-results-provides-full-year-2026-guidance</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/certara-reports-fourth-quarter-2025-financial-results-provides-full-year-2026-guidance</guid>
      <pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
      <description>FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj. EBITDA of $32.5M (-3%</description>
    </item>
    <item>
      <title>Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025</title>
      <link>https://6ix.com/company/certara-inc/news/certara-report-fourth-quarter-full-133000771</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/certara-report-fourth-quarter-full-133000771</guid>
      <pubDate>Thu, 29 Jan 2026 13:30:00 GMT</pubDate>
      <description>RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2025 before market open on Thursday, February 26th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least</description>
    </item>
    <item>
      <title>Cerrado Gold Announces Tacit Approval of Environmental Impact Assessment for the Lagoa Salgada Project, Portugal</title>
      <link>https://6ix.com/company/certara-inc/news/cerrado-gold-announces-tacit-approval-of-environmental-impact-assessment-for-the-lagoa-salgada-project-portugal</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/cerrado-gold-announces-tacit-approval-of-environmental-impact-assessment-for-the-lagoa-salgada-project-portugal</guid>
      <pubDate>Fri, 23 Jan 2026 00:01:00 GMT</pubDate>
      <description>Tacit approval reflects expiry of statutory deadline under Portuguese EIA legislationFormal certification to confirm tacit approval is being sought TORONTO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Cerrado Gold Inc. (“Cerrado” or the “Company”) announces that, pursuant to applicable provisions of Portuguese environmental law, the Environmental Impact Assessment (“EIA”) for the Lagoa Salgada Project, located in the Iberian Pyrite Belt of southern Portugal (the “Project”), is considered by Cerrado and it</description>
    </item>
    <item>
      <title>Certara Appoints Jon Resnick as Chief Executive Officer</title>
      <link>https://6ix.com/company/certara-inc/news/certara-appoints-jon-resnick-chief-executive-officer-2025-12-11</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/certara-appoints-jon-resnick-chief-executive-officer-2025-12-11</guid>
      <pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
      <description>Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step</description>
    </item>
    <item>
      <title>Certara Reports Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/certara-inc/news/certara-reports-third-quarter-2025-financial-results-2025-11-06</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/certara-reports-third-quarter-2025-financial-results-2025-11-06</guid>
      <pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
      <description>Updates Full Year 2025 Financial Guidance RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug</description>
    </item>
    <item>
      <title>Certara Automates Scientific Workflows with Phoenix® Cloud</title>
      <link>https://6ix.com/company/certara-inc/news/certara-automates-scientific-workflows-phoenixr-cloud-2025-11-04</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/certara-automates-scientific-workflows-phoenixr-cloud-2025-11-04</guid>
      <pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
      <description>New cloud capabilities cut time to create Tables, Figures, and Listings by 50% RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a</description>
    </item>
    <item>
      <title>Certara to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/certara-inc/news/certara-participate-upcoming-investor-conferences-2025-10-31</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/certara-participate-upcoming-investor-conferences-2025-10-31</guid>
      <pubDate>Fri, 31 Oct 2025 04:00:00 GMT</pubDate>
      <description>RADNOR, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company</description>
    </item>
    <item>
      <title>Certara Expands Biosimulation Market with AI-Driven QSP Platform</title>
      <link>https://6ix.com/company/certara-inc/news/certara-expands-biosimulation-market-ai-driven-qsp-platform-2025-10-30</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/certara-expands-biosimulation-market-ai-driven-qsp-platform-2025-10-30</guid>
      <pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
      <description>Certara IQ™ integrates AI and biosimulation to accelerate R&amp;D productivity, reduce risk, and deepen understanding of novel and complex therapies RADNOR, Pa.,</description>
    </item>
    <item>
      <title>Certara Scientists are Among the Topmost Cited Biopharma Researchers</title>
      <link>https://6ix.com/company/certara-inc/news/certara-scientists-are-among-topmost-cited-biopharma-researchers-2025-10-20</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/certara-scientists-are-among-topmost-cited-biopharma-researchers-2025-10-20</guid>
      <pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
      <description>Certara celebrates its 200 published papers and 11 scientists on Stanford/Elsevier top 2% cited researchers list in 2025 RADNOR, Pa., Oct. 20, 2025 (GLOBE</description>
    </item>
    <item>
      <title>Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025</title>
      <link>https://6ix.com/company/certara-inc/news/certara-report-third-quarter-2025-financial-results-november-6th-2025-2025-10-10</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/certara-report-third-quarter-2025-financial-results-november-6th-2025-2025-10-10</guid>
      <pubDate>Fri, 10 Oct 2025 04:00:00 GMT</pubDate>
      <description>RADNOR, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial</description>
    </item>
    <item>
      <title>Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster</title>
      <link>https://6ix.com/company/certara-inc/news/certara-launches-pinnacle-21r-enterprise-plus-deliver-regulatory-submissions-faster</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/certara-launches-pinnacle-21r-enterprise-plus-deliver-regulatory-submissions-faster</guid>
      <pubDate>Thu, 04 Sep 2025 04:00:00 GMT</pubDate>
      <description>Solution delivers a 50% reduction in time spent drafting mapping specifications, according to internal measurements RADNOR, Pa., Sept. 04, 2025 (GLOBE</description>
    </item>
    <item>
      <title>Certara Reports Second Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/certara-inc/news/certara-reports-second-quarter-2025-201500794</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/certara-reports-second-quarter-2025-201500794</guid>
      <pubDate>Wed, 06 Aug 2025 20:15:00 GMT</pubDate>
      <description>Reiterates Full Year 2025 Financial GuidanceRADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2025. Second Quarter Highlights: Revenue was $104.6 million, compared to $93.3 million in the second quarter of 2024, representing growth of 12%. Software revenue was $46.7 million, compared to $38.2 million in the second quarter of 2024, representing</description>
    </item>
    <item>
      <title>Certara Reports Second Quarter 2025 Financial Results </title>
      <link>https://6ix.com/company/certara-inc/news/certara-reports-second-quarter-2025-financial-results-2025-08-06</link>
      <guid isPermaLink="true">https://6ix.com/company/certara-inc/news/certara-reports-second-quarter-2025-financial-results-2025-08-06</guid>
      <pubDate>Wed, 06 Aug 2025 04:00:00 GMT</pubDate>
      <description>Reiterates Full Year 2025 Financial Guidance RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed</description>
    </item>
  </channel>
</rss>